HOME
|
CONTACT
About Nektar
Overview
Leadership
Management
Board of Directors
Partnering
Our Partners
Partner Case Studies
Partnering Events
Locations
Our Locations
Nektar Therapeutics Corporate Headquarters
Nektar Alabama
Nektar Therapeutics (India) Private Limited
Contact
R&D Pipeline
Products in Development
Product Pipeline
Oncology
- Etirinotecan pegol (NKTR-102)
CNS/Pain
- Naloxegol (NKTR-118)
- NKTR-181
- NKTR-192
Anti-Infectives
- NKTR-061 (BAY41-6551)
Clinical Trials Information
Investigator Resources
Approved Products
Scientific & Medical Event Calendar
Platform Technologies
Overview
Approved Products
Our Technology
Technology Overview
Small Molecule Polymer Conjugates
Pro-Drug Conjugates
Large Molecule Polymer Conjugates
Antibody Fragment Conjugates
Investor Relations
Overview
Financial Calendar & Presentations
News & E-mail Alerts
E-mail Alerts
Stock Information
Historic Stock Lookup
Analyst Coverage
Financial Information
SEC Filings
Annual Reports
Quarterly Results
Corporate Governance
Investor Contacts
Careers
Overview
Life at Nektar
Search Jobs
Benefits at Nektar
Overview
Benefits at San Francisco, California
Benefits at Huntsville, Alabama
Benefits at Hyderabad, India
Information for Recruiters
See Nektar's R&D pipeline of products in clinical development »
Learn more about our clinical trials »
See Nektar partners and case studies »
News Headlines
Events Calendar
May 21, 2013
2013 UBS Global Healthcare Conference
10:00 a.m. ET
Listen to this webcast
May 9, 2013
Q1 2013 Financial Results Conference Call
5:00 p.m. ET / 2:00 p.m. PT
Listen to this webcast
Media Highlights
BioCentury features Phase 1 NKTR-181 data in the Bernstein Report on BioBusiness
Drug Discovery News interviews Nektar's chief medical officer, Dr. Robert Medve, on NKTR-181 Phase 1 Data
Dr. Agustin Garcia presents NKTR-102 data in an oral abstract session at the 2011 ASCO Breast Cancer Symposium
Watch video clip »
Site Map
Privacy
Terms of Use
Compliance Policy
Trademarks
Site Users Guide
Copyright Nektar © 2013